Micki Klearman - 24 Jul 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Director
Signature
/s/ Marc Belsky, Attorney-in-Fact
Issuer symbol
KZR
Transactions as of
24 Jul 2023
Net transactions value
$0
Form type
4
Filing time
26 Jul 2023, 17:08:02 UTC
Previous filing
16 Jun 2023
Next filing
21 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -52,000 -100% 0 24 Jul 2023 Common Stock 52,000 $5.94 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Award +52,000 52,000 24 Jul 2023 Common Stock 52,000 $2.28 Direct F1, F2
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -26,000 -100% 0 24 Jul 2023 Common Stock 26,000 $5.59 Direct F2, F3
transaction KZR Stock Option (Right to Buy) Award +26,000 26,000 24 Jul 2023 Common Stock 26,000 $2.28 Direct F2, F3
transaction KZR Stock Option (Right to Buy) Disposed to Issuer -26,000 -100% 0 24 Jul 2023 Common Stock 26,000 $4.80 Direct F2, F3
transaction KZR Stock Option (Right to Buy) Award +26,000 26,000 24 Jul 2023 Common Stock 26,000 $2.28 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis following the vesting commencement date of June 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
F3 Fully vested and exercisable.